Key result
Anticoagulation for secondary stroke prevention in clinical practice achieved a recurrent stroke rate of 5.1% per year, comparable to the 3.6% per year observed in randomized trials.
Why the study?
Does anticoagulation therapy to maintain INR 2.0-3.0 prevent recurrent stroke in clinical practice comparably to randomized trials in stroke patients with atrial fibrillation?
Observational (n=288)
Does anticoagulation therapy to maintain INR 2.0-3.0 prevent recurrent stroke in clinical practice comparably to randomized trials in stroke patients with atrial fibrillation?
Absolute Event Rate: 5.1% vs 3.6%
Anticoagulation for secondary stroke prevention in clinical practice achieves outcomes comparable to randomized trials, though stroke subtype influences recurrence patterns.
No takes yet. Share an insight, caveat, or question.
Real-world anticoagulation achieves comparable recurrent stroke rates; extends trial evidence to clinical practice but leaves optimal strategies open for prospective validation.
Evans et al. (2000) conducted an observational in stroke with atrial fibrillation (n=288). anticoagulation therapy vs. European Atrial Fibrillation Trial (historical control) was evaluated on annual recurrent stroke rate. Anticoagulation for secondary stroke prevention in clinical practice achieved a recurrent stroke rate of 5.1% per year, comparable to the 3.6% per year observed in randomized trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: